GIP and obesity disorder: A new generation of anti-obesity medications (AOM), the Glucagon-like peptide-1 (GLP-1) / Gastric inhibitory polypeptide (GIP) / Glucagon receptor agonists, lead to 15–20% weight loss and are transforming the clinical care of people with obesity.